Abstract 377: Multifunctional magnetic nanoparticles for theranostic applications

Abstract

Abstract Nanoparticle technology address efficacy of cancer chemotherapy and diagnosis which can be potentially used for image guided drug delivery. Herein, we have developed a multi-layer approach for the synthesis of water-dispersible iron oxide theranostic nanoparticles for drug delivery (therapy) and magnetic resonance imaging (MRI) (diagnostic) applications. For this novel approach, iron oxide core nanoparticles were prepared by precipitation of iron salts in the presence of ammonia and coated with beta-cyclodextrin and pluronic polymer (F127). This formulation (F127250) was highly water dispersible which allowed encapsulation of the anti-cancer drug(s) in beta-cyclodextrin and pluronic polymer for sustained drug release. The F127250 formulation has exhibited superior hyperthermia effects over time under alternating magnetic field compared to pure magnetic nanoparticles (MNP) and beta-cyclodextrin coated nanoparticles (CD200). Additionally, the improved MRI characteristics were also observed for the F127250 formulation in agar gel and in cisplatin resistant ovarian cancer cells (A12780CP) compared to MNP and CD200 formulations. Furthermore, the drug loaded formulation of F127250 exhibited many folds of imaging contrast properties. Curcumin, a cancer preventive and anti-cancer drug, loaded formulation (F127250-CUR) exhibited almost equivalent inhibition effects on A2780CP (ovarian), MDA-MB-231 (breast), and PC3 (prostate) cancer cells even though curcumin release was only 40%. The improved therapeutic effects of this formulation were verified by examining ultra structural changes and molecular effects in cancer cells. Interestingly, F127250-CUR formulation also exhibited good haemo-compatibility. In conclusion, our data suggest that the F127250-CUR formulation can be effectively used for the delivery of anti-cancer drug drugs and cancer imaging and its potential clinical application. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 377. doi:10.1158/1538-7445.AM2011-377